Literature DB >> 25790764

Incidence and severity of paravalvular aortic regurgitation with multidetector computed tomography nominal area oversizing or undersizing after transcatheter heart valve replacement with the Sapien 3: a comparison with the Sapien XT.

Tae-Hyun Yang1, John G Webb2, Philipp Blanke2, Danny Dvir2, Nicolaj C Hansson3, Bjarne L Nørgaard3, Christopher R Thompson2, Martyn Thomas4, Olaf Wendler5, Alec Vahanian6, Dominique Himbert6, Susheel K Kodali7, Rebecca T Hahn7, Vinod H Thourani8, Gerhard Schymik9, Bruce Precious2, Adam Berger2, David A Wood2, Philippe Pibarot10, Josep Rodés-Cabau10, Wael A Jaber11, Martin B Leon7, Thomas Walther12, Jonathon Leipsic13.   

Abstract

OBJECTIVES: This study sought to compare the influence of the extent of multidetector computed tomography (MDCT) area oversizing on the incidence of paravalvular aortic regurgitation (PAR) between the Sapien 3 and the Sapien XT transcatheter heart valve (THV) to define a new MDCT sizing guideline suitable for the Sapien 3 platform.
BACKGROUND: The inverse relationship of PAR occurrence and oversizing has been demonstrated for the Sapien XT but the incidence of PAR with comparable oversizing with the Sapien 3 is not known.
METHODS: Sixty-one prospectively enrolled patients who underwent transcatheter aortic valve replacement with the Sapien 3 THV were compared with 92 patients who underwent transcatheter aortic valve replacement with the Sapien XT THV. Patients were categorized depending on the degree of MDCT area oversizing percentage: undersizing (below 0%), 0% to 5%, 5% to 10%, and above 10%. The primary endpoint was mild or greater PAR on transthoracic echocardiography.
RESULTS: Mild or greater PAR was present in 19.7% of patients (12 of 61) in the Sapien 3 group and in 54.3% of patients (50 of 92) in the Sapien XT group (p < 0.01). The Sapien 3 group, compared with the Sapien XT group, consistently demonstrated significantly lower rates of mild or greater PAR except for oversizing >10% (p for interaction = 0.54). Moderate or severe PAR rates were also lower in the Sapien 3 group than in the Sapien XT group (3.3% vs. 13.0%, p = 0.04). In the Sapien 3 group, a MDCT area oversizing percentage value of ≤4.17% was identified as the optimal cutoff value to discriminate patients with or without mild or greater PAR.
CONCLUSIONS: Our retrospective analysis suggests that the Sapien 3 THV displays significantly lower rates of PAR than does the Sapien XT THV. A lesser degree of MDCT area oversizing may be employed for this new balloon-expandable THV.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  annulus area; multidetector computed tomography; paravalvular aortic regurgitation; transcatheter aortic valve replacement

Mesh:

Year:  2015        PMID: 25790764     DOI: 10.1016/j.jcin.2014.10.014

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  27 in total

Review 1.  How to Image and Manage Prosthesis-Related Complications After Transcatheter Aortic Valve Replacement.

Authors:  Nina C Wunderlich; Jörg Honold; Martin J Swaans; Robert J Siegel
Journal:  Curr Cardiol Rep       Date:  2021-07-01       Impact factor: 2.931

Review 2.  Noninvasive Cardiac Imaging in Patients with Known and Suspected Coronary Artery Disease: What is in it for the Interventional Cardiologist?

Authors:  Gaston A Rodriguez-Granillo; Roxana Campisi; Patricia Carrascosa
Journal:  Curr Cardiol Rep       Date:  2016-01       Impact factor: 2.931

3.  Applicability of next generation balloon-expandable transcatheter heart valves in aortic annuli exceeding formally approved dimensions.

Authors:  Andreas Schaefer; Matthias Linder; Hendrik Treede; Florian Deuschl; Niklas Schofer; Moritz Seiffert; Yvonne Schneeberger; Stefan Blankenberg; Hermann Reichenspurner; Ulrich Schaefer; Lenard Conradi
Journal:  Clin Res Cardiol       Date:  2015-12-17       Impact factor: 5.460

4.  Predictors of right ventricular pacing and pacemaker dependence in transcatheter aortic valve replacement patients.

Authors:  Esseim Sharma; Antony F Chu
Journal:  J Interv Card Electrophysiol       Date:  2017-12-19       Impact factor: 1.900

5.  Impact of sigmoid septum on periprocedural outcomes following transcatheter aortic valve implantation using current-generation valves.

Authors:  Masaki Tsuda; Yasuyuki Egami; Yutaka Matsuhiro; Hitoshi Nakamura; Koji Yasumoto; Naotaka Okamoto; Yasuharu Matsunaga-Lee; Masamichi Yano; Masami Nishino; Jun Tanouchi
Journal:  Int J Cardiovasc Imaging       Date:  2021-11-29       Impact factor: 2.357

6.  3D printing based on cardiac CT assists anatomic visualization prior to transcatheter aortic valve replacement.

Authors:  Beth Ripley; Tatiana Kelil; Michael K Cheezum; Alexandra Goncalves; Marcelo F Di Carli; Frank J Rybicki; Mike Steigner; Dimitrios Mitsouras; Ron Blankstein
Journal:  J Cardiovasc Comput Tomogr       Date:  2015-12-12

Review 7.  Annular Rupture During Transcatheter Aortic Valve Implantation: Predictors, Management and Outcomes.

Authors:  J J Coughlan; Thomas Kiernan; Darren Mylotte; Samer Arnous
Journal:  Interv Cardiol       Date:  2018-09

8.  Avoiding Coronary Occlusion and Root Rupture in TAVI - The Role of Pre-procedural Imaging and Prosthesis Selection.

Authors:  Marco Barbanti
Journal:  Interv Cardiol       Date:  2015-05

9.  A Glimpse into the Future: In 2020, Which Patients will Undergo TAVI or SAVR?

Authors:  Crochan J O'Sullivan; Peter Wenaweser
Journal:  Interv Cardiol       Date:  2017-05

10.  Incidence and predictors of prosthesis-patient mismatch after TAVI using SAPIEN 3 in Asian: differences between the newer and older balloon-expandable valve.

Authors:  Masaki Miyasaka; Norio Tada; Masataka Taguri; Shigeaki Kato; Yusuke Enta; Masaki Hata; Yusuke Watanabe; Toru Naganuma; Masahiro Yamawaki; Futoshi Yamanaka; Shinichi Shirai; Hiroshi Ueno; Kazuki Mizutani; Minoru Tabata; Kensuke Takagi; Masanori Yamamoto; Kentaro Hayashida
Journal:  Open Heart       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.